ELICIO THERAPEUTICS INC. - COMMON STOCK

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

30 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

22 Jan 2025 06:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

03 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

13 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting

07 Nov 2024 15:05:02 By Nasdaq GlobeNewswire

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

31 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

16 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

17 Sep 2024 07:31:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

13 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

13 Aug 2024 15:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note

12 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering

28 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Proposed Public Offering

27 Jun 2024 15:05:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P

27 Jun 2024 15:01:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

18 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

23 May 2024 16:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

15 May 2024 15:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

25 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

05 Apr 2024 15:30:00 By Nasdaq GlobeNewswire